TY  - JOUR
PB  - American Association for Cancer Research
ID  - discovery10143833
N2  - PIK3CA, which encodes the p110? catalytic subunit of PI3K?, is one of the most frequently genetically activated kinases in solid tumors. In this issue of Cancer Discovery, Song and colleagues report that the related PI3K? inhibitors taselisib and inavolisib trigger receptor tyrosine kinase (RTK)-dependent degradation of the mutant p110? protein in breast cancer cells that are positive for HER2 RTK, limiting feedback-mediated drug resistance and potentially widening the therapeutic index of PI3K? inhibition.See related article by Song et al., p. 204.
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Oncology
EP  - 22
AV  - public
Y1  - 2022/01/12/
TI  - Precision Targeting of Mutant PI3K? in Cancer by Selective Degradation
SN  - 2159-8274
UR  - https://doi.org/10.1158/2159-8290.CD-21-1411
A1  - Vanhaesebroeck, Bart
A1  - Burke, John E
A1  - Madsen, Ralitsa R
JF  - Cancer Discovery
VL  - 12
SP  - 20
IS  - 1
ER  -